Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 652-658

  Lieu, C H ^a   Lambert, L A ^a   Wolff, R A ^a   Eng, C ^a   Zhang, N ^a   Wen, S ^a   Rafeeq, S ^a   Taggart, M ^a   Fournier, K ^a   Royal, R ^a   Mansfield, P ^a   Overman, M J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Appendiceal cancers; Cytoreductive surgery; Poorly differentiated; Retrospective review; Signet ring

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; APPENDIX CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; POORLY DIFFERENTIATED APPENDIX ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNET RING CARCINOMA; SIGNET RING CELL APPENDIX ADENOCARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; CARCINOMA, SIGNET RING CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84857599592     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr279     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Connor S, Hanna G, Frizelle F. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998; 41: 75-80.
3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7: 69-76.
4. Miner TJ, Shia J, Jaques DP et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005; 241: 300-308.
5. Ronnett BM, Zahn CM, Kurman RJ et al. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995; 19: 1390-1408.
6. Misdraji J, Yantiss RK, Graeme-Cook FM et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27: 1089-1103.
7. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 2007; 245: 104-109.
8. Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727-731.
9. Stewart JH IV, Shen P, Russell GB et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13: 624-634.
10. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240: 278-285.
11. Shapiro JF, Chase JL, Wolff RA et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 2010; 116(2): 316-322.
12. Smith J, Kemeny N, Caldwell C et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992; 70: 396-401.
13. Farquharson AL, Pranesh N, Witham G et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008; 99: 591-596.
14. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008; 15: 526-534.
15. Kabbani W, Houlihan PS, Luthra R et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 2002; 15: 599-605.
16. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.